iPS Cells & Regenerative Medicine– category –
-
Single-Dose CRISPR Therapy Slashes LDL Cholesterol by 52.5%, Triglycerides by 47.8% in Landmark Phase 1 Trial
Medical Xpress USA Overview Vertex Pharmaceuticals' VERVE-101, a one-time CRISPR-Cas9 gene editing therapy, has achieved significant results in a Phase 1 trial, safely reducing LDL cholesterol by 52.5% and triglycerides by 47.8% in patie... -
iPS Cells & Regenerative Medicine Weekly Report September 6, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 06, 2026 (PDF) — Download Weekly Report September 06, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe... -
Genprex Taps Andelyn Biosciences to Accelerate Manufacturing Scale-Up for Diabetes Gene Therapy Program
Contract Pharma USA Overview Clinical-stage company Genprex has selected Andelyn Biosciences as its CDMO to scale up manufacturing for its diabetes gene therapy program. Leveraging its proprietary Curator Cell and Gene Therapy Platform, ... -
The Unspoken Challenge: Cell Therapy Developers Lack Full Product Understanding at Clinical Stage
VOKA Unknown Overview A critical challenge in cell therapy development is that developers often lack a complete understanding of their products even at the point of patient administration. Participants in Cell&Gene Foundry concluded ... -
Cellipont Bioservices’ Texas Facility Propels Six Client Cell Therapy Programs to Expected 2026 IND Submissions
PR Newswire (Cellipont Bioservices) USA Overview Cellipont Bioservices, a cell therapy CDMO, announced that its Texas facility has supported six client projects anticipated to reach Investigational New Drug (IND) submission in 2026. This... -
Biotech Alliances Surge: Alteogen-Novartis Subcutaneous Drug Delivery Deal and NewBiologix-Synastra Gene Therapy Manufacturing Partnership Highlight Industry Trends
PharmExec Unknown Overview Alteogen has signed an option and license agreement with Novartis for subcutaneous drug development, while NewBiologix and Synastra announced a partnership to develop stable production cell lines for Duchenne m... -
Overcoming Commercialization Hurdles for iPSC Therapeutics: Regulatory Compliance and Accessible Manufacturing Strategies
Technology Networks Unknown Overview Commercializing iPSC-based therapeutics faces significant challenges in regulatory compliance and ensuring patient accessibility, as many therapies originate from academic settings without large-scale... -
Cell Therapy Market Sees 26% Revenue Growth, Driven by Commercial Successes and Strategic Investment in Scalable Manufacturing
New Market Pitch Unknown Overview The cell therapy market is experiencing robust growth, with key commercial products reporting approximately 26% year-over-year revenue increase. Carvykti, for instance, treated over 10,000 clinical and c... -
Century Therapeutics Seeks Director to Lead Large-Scale Cell Therapy Process Development for Clinical and Commercial Programs
JobLeads (Century Therapeutics, Inc.) USA Overview Century Therapeutics is recruiting a Director of Large-Scale Process Development to lead scale-up strategies for bioreactor expansion, harvesting, and fill/finish operations in their cli... -
UniQure Files for FDA Approval of Huntington’s Gene Therapy AMT-130, Pursuing Breakthrough for Neurological Disorder
BioPharma Dive USA Overview After overcoming previous regulatory challenges, UniQure has submitted its gene therapy AMT-130 for FDA approval, aiming to be the first medicine to address the underlying cause of Huntington's disease. The co...
